Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Lytgobi Newest Drug Approved for Patients with FGFR2-Positive Cholangiocarcinoma

October 2022 Vol 8 No 5

On September 30, 2022, the FDA approved Lytgobi (futibatinib; from Taiho Oncology), a tyrosine kinase inhibitor (a targeted therapy), for the treatment of adults with unresectable (can’t be removed by surgery), locally advanced or metastatic (spreading) intrahepatic cholangiocarcinoma (a type of gastrointestinal [GI] cancer) associated with an FGFR2 gene fusion or other rearrangements.

Lipika Goyal, MD, MPhil
Lipika Goyal, MD, MPhil

“Lytgobi is a key example of the potential of precision medicine in [cholangiocarcinoma] and represents another advance in the treatment of this rare and challenging disease,” said Lipika Goyal, MD, MPhil, of Massachusetts General Hospital Cancer Center.

The FDA approved Lytgobi for cholangiocarcinoma based on results of a multicenter clinical trial that included 103 patients with unresectable, locally advanced, intrahepatic cholangiocarcinoma associated with the FGFR2 biomarker.

Of the 103 patients in the study, 43 (42%) had a partial response to Lytgobi, and the average duration of response was 9.7 months.

The most common side effects reported in 20% or more of patients using Lytgobi are nail problems, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, hair loss, abdominal pain, dry skin, arthralgia, dysgeusia, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting.

Recommended For You